Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed
These results show that, for most anti-CGRP mAbs, a low number of participants (< 10) with migraine need to be treated to achieve one person with a ≥ 50% or ≥ 75% reduction in MMDs over Weeks 1-12, with CPR ranging from £4647 (eptinezumab 100 mg) to £21,862 (fremanezumab 675 mg/q).
Authors
- Ravinder Phul
- Simona Sacco (ORCID: https://orcid.org/0000-0003-0651-1939)
- Xin Ying Lee (ORCID: https://orcid.org/0000-0002-1102-3756)
- Susanne F. Awad (ORCID: https://orcid.org/0000-0002-5060-7404)
- Line Pickering (ORCID: https://orcid.org/0000-0002-3062-8881)
- Dimos D. Mitsikostas (ORCID: https://orcid.org/0000-0002-4691-3388)
- Rikke Kongerslev
Institutions
- Lundbeck (Denmark) (DK)
- National and Kapodistrian University of Athens (GR)
- University of L'Aquila (IT)
- Eginition Hospital (GR)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1007/s12325-025-03348-8
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47